PROX1 and chronic myelogenous leukemia, BCR-ABL1 positive: When compared with TKI responders, CML patients with inadequate response had significantly higher expression of LN989, PROX1-AS1, SENCR, LN892, and KIF25-AS1 (Figure 3C).